Director/PDMR Shareholding (Replacement)

RNS Number : 8001B

GlaxoSmithKline PLC

20 April 2012

 



This announcement replaces the original announcement released on 18 April 2012 at 15.27 (RNS No: 6125B)

Due to an administrative error by the Administrators of the GlaxoSmithKline Performance Share Plan the change in one of the under-mentioned person's notional interests in the Ordinary Shares of GlaxoSmithKline plc indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 18 April 2012.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

 Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 18 April 2012 of an increase in their notional interests in Ordinary Shares at a price of 1420 pence per Ordinary Share and American Depositary Shares (ADSs) at a price of $45.47 per ADS following the notional re-investment of the dividend paid to shareholders on 12 April 2012.

	Ordinary Shares	ADSs
Sir Andrew Witty	19,276.728
Dr M M Slaoui		5,763.192
Mr S Dingemans	3,717.248
Mr S M Bicknell	2,014.250
Mrs D P Connelly		2,869.501
Mr M Dunoyer	2,482.552
Mr E J Gray	4,180.417
Mr S A Hussain	5,297.088
Mr W C Louv		1,678.711
Dr D Pulman		2,501.300
Mr D S Redfern	2,571.532
Ms C Thomas	3,740.225
Mr P C Thomson	284.435
Mr D E Troy		3,202.482
Dr P J T Vallance	3,468.230
Ms E Walmsley	2,521.782
Mr C Weber	926.303*
Mrs V A Whyte	284.435

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

18 April 2012

 

END

 

 

RDSEASLEAEXAEFF